Insulin glargine 300 U/ml versus insulin degludec 100 U/ml in type 2 diabetic patients treated with basal-bolus insulin therapy
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000019969
- Lead Sponsor
- Shiraiwa Medical Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
- treated with anti-diabetic agents other than insulin - difficult to perform self-monitoring of blood glucose - severe hepatic, renal and/or cardiac disease - hypersensitivity to insulin degludec and/or insulin glargine - pregnant or breast-feeding females. - Patients who are judged by the investigator to be inappropriate for this study for any other reason.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method daily profiles of glucose levels
- Secondary Outcome Measures
Name Time Method